The pharmacological inhibition of extracellular GrB in the chorio-retinal space may be a potentially therapeutic option that can correct the pathologic ECM remodelling induced by GrB, thereby restraining its concomitant effects and the pathologic characteristics of CNV in AMD. Here, GZMB is linked to age-related macular degeneration.